Show simple item record

dc.contributor.authorPridgen, Eric M
dc.contributor.authorAlexis, Frank
dc.contributor.authorFarokhzad, Omid Cameron
dc.date.accessioned2016-11-02T20:23:50Z
dc.date.issued2015
dc.identifier.citationPridgen, Eric M, Frank Alexis, and Omid C Farokhzad. 2015. Polymeric Nanoparticle Drug Delivery Technologies for Oral Delivery Applications. Expert Opinion on Drug Delivery 12 (9) (March 26): 1459–1473. doi:10.1517/17425247.2015.1018175.en_US
dc.identifier.issn1742-5247en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29293164
dc.description.abstractIntroduction: Many therapeutics are limited to parenteral administration. Oral administration is a desirable alternative because of the convenience and increased compliance by patients, especially for chronic diseases that require frequent administration. Polymeric nanoparticles are one technology being developed to enable clinically feasible oral delivery. Areas Covered: This review discusses the challenges associated with oral delivery. Strategies used to overcome gastrointestinal barriers using polymeric nanoparticles will be considered, including mucoadhesive biomaterials and targeting of nanoparticles to transcytosis pathways associated with M cells and enterocytes. Applications of oral delivery technologies will also be discussed, such as oral chemotherapies, oral insulin, treatment of inflammatory bowel disease, and mucosal vaccinations. Expert Opinion: There have been many approaches used to overcome the transport barriers presented by the gastrointestinal tract, but most have been limited by low bioavailability. Recent strategies targeting nanoparticles to transcytosis pathways present in the intestines have demonstrated that it is feasible to efficiently transport both therapeutics and nanoparticles across the intestines and into systemic circulation after oral administration. Further understanding of the physiology and pathophysiology of the intestines could lead to additional improvements in oral polymeric nanoparticle technologies and enable the translation of these technologies to clinical practice.en_US
dc.language.isoen_USen_US
dc.publisherInforma Healthcareen_US
dc.relation.isversionofdoi:10.1517/17425247.2015.1018175en_US
dc.relation.hasversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835173/en_US
dash.licenseOAP
dc.subjectInsulinen_US
dc.subjectM Cellsen_US
dc.subjectMucoadhesivesen_US
dc.subjectMucosal Vaccinationsen_US
dc.subjectOral Deliveryen_US
dc.subjectPolymeric Nanoparticlesen_US
dc.subjectTranscytosisen_US
dc.subjectChemotherapyen_US
dc.subjectInflammatory Bowel Diseaseen_US
dc.titlePolymeric nanoparticle drug delivery technologies for oral delivery applicationsen_US
dc.typeJournal Articleen_US
dc.description.versionAccepted Manuscripten_US
dc.relation.journalExpert Opinion on Drug Deliveryen_US
dash.depositing.authorFarokhzad, Omid Cameron
dc.date.available2016-11-02T20:23:50Z
dc.identifier.doi10.1517/17425247.2015.1018175*
dash.contributor.affiliatedFarokhzad, Omid


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record